Paris, France and Gent, Belgium, November 13, 2006 – 18h00 – Sanofi-aventis, Innogenetics, and Inserm, through its subsidiary called Inserm Transfert, announced today the conclusion of a collaborative research agreement in the field of Alzheimer’s disease.

This collaboration agreement is signed for an initial period of 2 years, with an option for Sanofiaventis to obtain an exclusive worldwide license on the results arising from the research program in the therapeutics field. Innogenetics will have an exclusive worldwide license in the diagnostics field.
The present agreement is built on intellectual property and a research collaboration between Innogenetics and Inserm-Lille (U-422) on the development of new diagnostic tools for Alzheimer’s disease (AD) dating back from 2002. The results of the collaboration will allow to study the role of specific forms of the key Alzheimer protein amyloid beta, and related technology, as targets for new therapeutic avenues for AD. Based on the technology and products provided by Innogenetics and Inserm, Sanofi will evaluate different
products against diverse forms of the beta protein in a passive immunization program.
In return for providing Sanofi-aventis access to their technology and services, Innogenetics and Inserm- Transfert will receive upfront and research fees.
In the event Sanofi-aventis exercises its license option, Innogenetics and Inserm-Transfert will be entitled to milestone payments and royalties on future sales of therapeutic products resulting from this collaboration.
Financial terms of the agreement are not disclosed.
Frank Morich, CEO of Innogenetics, commented: "This agreement is a significant valorization of our discovery, and development capabilities, and of our intellectual property in the field of Alzheimer’s disease.
The combination of technologies and expertise from 3 different parties, each having outstanding know-how in their field, creates a unique alliance. This joint effort will address a medical need in Alzheimer’s disease and will add value for Innogenetics and its shareholders.”

About Sanofi-aventis
Sanofi-aventis is the world’s third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, Sanofi-aventis is developing leading positions in seven major therapeutic
areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

About INSERM and Inserm Transfert
The French National Institute for Health and Medical Research (INSERM) is the only French public research institute totally devoted to biological, medical and public health research. INSERM consists of above 13,000 scientists and its activity focuses on the study of all human illness inside 360 research units and 24 Clinical Investigation Centres created in partnership with public hospitals. INSERM’s mission is to accelerate the access to research results for patients, medical actors and national and international partners, by the
development of innovative products and services generated by its researches.
Inserm Transfert, subsidiary of INSERM is a public limited company that contributes to the transfer of research to industry and its successful development by industry. This is done through biotech start-up creation, business support, industrial funded and European Commission granted projects and by facilitating the development of INSERM s innovative technologies and by offering new entrepreneurial opportunities to researchers. Inserm Transfert manages the development and the commercialization of Intellectual Property
and know-how arising from Inserm research activity. Inserm-Transfert works in conjunction with the French network of incubators and participates in seed and venture capital funds.

About Innogenetics
Innogenetics is an international biopharmaceutical company building parallel businesses in the areas of specialty diagnostics and therapeutic vaccines.
In 2005, total revenues (product sales, royalties, and license fees) reached €48.6 million, with a profitable Diagnostics Division. Its Diagnostics Division develops a large number of specialty products covering three
areas: infectious diseases (hepatitis C, hepatitis B, and HIV), genetic testing (HLA tissue typing and cystic fibrosis), and neurodegeneration (Alzheimer’s disease). In its Therapeutics Division, Innogenetics focuses on
the development of therapeutic vaccines to address unmet medical needs in the field of infectious diseases, with two compounds now in clinical trials (hepatitis C in phase IIb and hepatitis B in phase I).
Founded in 1985, Innogenetics is listed on Euronext Brussels [Ticker: INNX]. Innogenetics’ headquarters are in Gent, Belgium, with sales subsidiaries in France, Germany, Italy, Spain, Brazil, and the United States.
Innogenetics employs 525 people worldwide and has a market capitalization of approximately €305 million.